Healthcare provider profile · identity verified

Eli R Stark, AGNP

Nurse Practitioner · HOLYOKE, MA · NPI 1386294080

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	345	101
Gabapentin	Gabapentin	250	43
Lisinopril	Lisinopril	161	51
Omeprazole	Omeprazole	158	46
Amlodipine Besylate	Amlodipine Besylate	135	44
Ventolin Hfa	Albuterol Sulfate	133	37
Levothyroxine Sodium	Levothyroxine Sodium	130	25
Tramadol Hcl	Tramadol Hcl	129	32
Metformin Hcl	Metformin Hcl	121	39
Alcohol Prep Pads	Alcohol Antiseptic Pads	120	27
Trulicity	Dulaglutide	115	22
Hydrochlorothiazide	Hydrochlorothiazide	108	32
Metoprolol Succinate	Metoprolol Succinate	104	26
Pantoprazole Sodium	Pantoprazole Sodium	94	21
Albuterol Sulfate Hfa	Albuterol Sulfate	93	28
Metformin Hcl Er	Metformin Hcl	89	25
Fluticasone Propionate	Fluticasone Propionate	86	30
Jardiance	Empagliflozin	84	27
Novolog Flexpen	Insulin Aspart	84	14
Rosuvastatin Calcium	Rosuvastatin Calcium	76	27
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	74	21
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	70	19
Losartan Potassium	Losartan Potassium	69	22
Eliquis	Apixaban	66	12
Oxycodone Hcl	Oxycodone Hcl	65	26
Trazodone Hcl	Trazodone Hcl	65	13
Ozempic	Semaglutide	59	suppressed
Famotidine	Famotidine	54	18
Arnuity Ellipta	Fluticasone Furoate	53	11
Tamsulosin Hcl	Tamsulosin Hcl	50	13
Tresiba Flextouch U-100	Insulin Degludec	49	suppressed
Diclofenac Sodium	Diclofenac Sodium	48	19
Incruse Ellipta	Umeclidinium Bromide	46	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	45	13
Carvedilol	Carvedilol	44	suppressed
Sertraline Hcl	Sertraline Hcl	44	11
Ibuprofen	Ibuprofen	42	15
Montelukast Sodium	Montelukast Sodium	40	13
Clonidine Hcl	Clonidine Hcl	38	suppressed
Lidocaine	Lidocaine	38	12
Simvastatin	Simvastatin	38	15
Furosemide	Furosemide	36	suppressed
Topiramate	Topiramate	36	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Pentips Pen Needle	Pen Needle, Diabetic	33	suppressed
Enalapril Maleate	Enalapril Maleate	31	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	29	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	29	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	28	suppressed
Ketoconazole	Ketoconazole	28	11
Venlafaxine Hcl Er	Venlafaxine Hcl	28	suppressed
Clonazepam	Clonazepam	27	suppressed
Descovy	Emtricitabine/Tenofov Alafenam	27	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	27	suppressed
Januvia	Sitagliptin Phosphate	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	suppressed
Rybelsus	Semaglutide	27	suppressed
Glipizide	Glipizide	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Nifedipine Er	Nifedipine	25	suppressed
Atenolol	Atenolol	23	suppressed
Breo Ellipta	Fluticasone/Vilanterol	23	suppressed
Clotrimazole	Clotrimazole	23	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	12
Doxepin Hcl	Doxepin Hcl	23	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	23	suppressed
Warfarin Sodium	Warfarin Sodium	23	suppressed
Glipizide Er	Glipizide	22	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	22	suppressed
Easy Touch Pen Needle	Pen Needle, Diabetic	21	suppressed
Lorazepam	Lorazepam	21	suppressed
Ezetimibe	Ezetimibe	20	suppressed
Naproxen	Naproxen	20	suppressed
Tradjenta	Linagliptin	20	suppressed
Morphine Sulfate Er	Morphine Sulfate	19	suppressed
Valsartan	Valsartan	19	suppressed
Varenicline Tartrate	Varenicline Tartrate	19	suppressed
Buspirone Hcl	Buspirone Hcl	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Glimepiride	Glimepiride	18	suppressed
Pregabalin	Pregabalin	18	suppressed
Ultiguard Safepack-Pen Needle	Pen Needle, Diabetic,disp Unit	18	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	18	suppressed
Allopurinol	Allopurinol	17	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Citalopram Hbr	Citalopram Hydrobromide	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	17	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Pravastatin Sodium	Pravastatin Sodium	17	suppressed
Clobetasol Propionate	Clobetasol Propionate	16	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	16	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	15	suppressed
Alprazolam	Alprazolam	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Lidocaine Hcl Viscous	Lidocaine Hcl	14	suppressed
Meloxicam	Meloxicam	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	13	suppressed
Chlorthalidone	Chlorthalidone	13	suppressed
Oxycontin	Oxycodone Hcl	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Ropinirole Hcl	Ropinirole Hcl	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Brilinta	Ticagrelor	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	12	suppressed
Sure Comfort Pen Needle	Pen Needle, Diabetic	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	11	suppressed
Repaglinide	Repaglinide	11	suppressed
Torsemide	Torsemide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error